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EVALUATING THE NCCN CLINICAL CRITERIA FOR HEREDITARY BREAST AND 
OVARIAN CANCER SYNDROME GENETIC TESTING 
 
Caiqian Wu, BS, BA 
Advisory Professor: Molly Daniels, MS 
 
Hereditary Breast and Ovarian Cancer (HBOC) syndrome predisposes females with a BRCA1 or 
BRCA2 mutation to an up to 85% lifetime risk for breast cancer and an up to 40% lifetime risk for 
ovarian cancer. It is crucial for individuals with HBOC to be identified to allow for proper 
screening, management, and identification of at-risk family members in order to reduce mortality. 
The National Comprehensive Cancer Network (NCCN) has established clinical guidelines for 
when to recommend BRCA1/2 testing. A retrospective chart review of 1123 M.D. Anderson 
Cancer Center breast cancer patients was performed in order to evaluate the positive predictive 
values (PPVs) of 14 individual criterion for predicting a BRCA1/2 mutation. Two criteria had 
PPVs significantly below 10%. Only 2 of 115 patients recommended for testing based solely on 
the criterion of “diagnosed with breast cancer ≤45 years of age”  tested positive for a pathogenic 
mutation at a PPV of 1.6% (0.2-6%, 95% CI), which is significantly below the clinical utility cut-
off of 10% (p = 0.001). Additionally, 0 out of 37 individuals who underwent testing based on the 
criterion, “diagnosed with breast cancer at any age with ≥2 close blood relatives with breast 
cancer at any age” tested positive (0-9%, 95% CI).  Overall, an individual who meets more than 
one criterion has a PPV of 12% while those who meet only one criterion has a PPV of 3.52%, 
which is significantly below 10% (p<.0001) for predicting BRCA1/2 positivity. This data can 
help provide more personalized risks and anticipatory guidance for patients in their decision to 
pursue genetic testing.  
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INTRODUCTION 
Hereditary Breast and Ovarian Cancer (HBOC) syndrome is a cancer susceptibility 
syndrome that predisposes individuals to significant elevated risks for breast and ovarian cancer 
over that of the general population. Females with HBOC have an up to 85% lifetime risk for 
breast cancer, an up to 40% lifetime risk for ovarian cancer, and are at an increased risk for a 
second primary breast cancer as well as other cancers such as pancreatic cancer (Antoniou, 
Pharoah, Narod, Risch, Eyfjord, Hopper, Loman, Olsson, Johannsson, Borg, Pasini, Radice, 
Manoukian, Eccles, Tang, Olah, Anton-Culver, Warner, Lubinski, Gronwald, Gorski, Tulinius, 
Thorlacius, Eerola, Nevanlinna, Syrjakoski, Kallioniemi, Thompson, Evans, Peto, Lalloo, Evans, 
& Easton, 2003; Chen & Parmigiani, 2007; Ford, Easton, Stratton, Narod, Goldgar, Devilee, 
Bishop, Weber, Lenoir, Chang-Claude, Sobol, Teare, Struewing, Arason, Scherneck, Peto, 
Rebbeck, Tonin, Neuhausen, Barkardottir, Eyfjord, Lynch, Ponder, Gayther, & Zelada-Hedman, 
1998). Males with HBOC are at an increased risk for male breast cancer, pancreatic cancer, and 
prostate cancer. At approximately 234,190 new cases estimated for 2015 in the United States, 
breast cancer is one of the most common cancers (American Cancer Society, 2015).   The 
prevalence of carrying a BRCA1 or BRCA2 mutation is estimated at 1 in 400 to 1 in 800 
individuals in the general non-Ashkenazi Jewish population, and approximately 1%-6% of female 
breast cancers are associated with a BRCA1 or BRCA2 mutation (Frank & Critchfield, 2001; 
McClain, Palomaki, Nathanson, & Haddow, 2005; Petrucelli, Daly, & Feldman, 2010). It is 
imperative that these very high-risk individuals to be identified amongst the hundreds of 
thousands of breast cancer cases that have a more sporadic cause, without accumulating 
significant costs and harms associated with testing unsuitable candidates. 
The National Comprehensive Cancer Network (NCCN) is a nonprofit alliance of 26 of 
the leading cancer centers in the United States devoted to research, education, and improvement 
of care for cancer patients (National Comprehensive Cancer Network, 2015). In 1996, the NCCN 
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began a program to develop comprehensive clinical practice guidelines for management of the 
most common tumors reflecting a process of consensus relying on evaluation of evidence and 
structured feedback (Winn, Botnick, & Dozier, 1996). These guidelines are revised twice a year 
to incorporate the most recent literature and developments in the field. One practice guideline was 
specifically developed for “Genetic/Familial High-Risk Assessment: Breast and Ovarian”. These 
guidelines describe the recommendations for detection and management of individuals at an 
increased risk for breast and/or ovarian cancer. Included in the guidelines are clinical criteria for 
when to recommend testing for the BRCA1 and BRCA2 genes.   
As genetic information may have significant implications for the individual undergoing 
testing, it is important to consider the value of genetic testing for each individual. Benefits to 
genetic testing may include the potential for surveillance and risk-reducing surgeries which may 
significantly reduce cancer-associated mortality as well as relief from uncertainty (Nelson, 
Pappas, Zakher, Mitchell, Okinaka-Hu, & Fu, 2014) Costs associated with genetic testing may 
include anxiety from cancer risks, fear of genetic discrimination, and financial burden (Nelson, 
Pappas, Zakher, Mitchell, Okinaka-Hu, & Fu, 2014). HBOC is inherited in an autosomal 
dominant manner, meaning that each first degree relative of an individual with a mutation in 
BRCA1 or BRCA2 has a 50% chance of also having inherited the mutation. Identifying a 
deleterious mutation in the family also allows for at-risk relatives to undergo predictive testing 
and to determine if additional family members will need to undergo high-risk screening and 
management. 
The purpose of this study was to evaluate the clinical utility of the NCCN criteria for 
when to recommend BRCA1 and BRCA2 genetic testing. A widely accepted threshold of clinical 
utility for the positive predictive value of genetic testing is 10%, at which point there is a balance 
between the benefits to genetic testing versus its costs (Roberts, Vogelstein, Parmigiani, Kinzler, 
Vogelstein, & Velculescu, 2012). Clinical molecular genetic testing for the BRCA genes has been 
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available to patients at MD Anderson since its launch in 1996, allowing for a retrospective data 
review of genetic testing results in our patient population. Even though each of the genetic testing 
criteria put forth in the NCCN guidelines is weighted equally in recommending referral to genetic 
testing, we expect some criteria to be more predictive than others. As the current guidelines only 
require one criterion to be fulfilled in order to recommend genetic testing, our study aims to 
evaluate the clinical utility of individual clinical criteria for recommending BRCA1/2 testing in 
patients with breast cancer.  
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METHODS 
The NCCN guidelines in effect during the study period was “Genetic/Familial High-Risk 
Assessment: Breast and Ovarian Version 2.2014” (National Comprehensive Cancer Network, 
2014). This study specifically aims to clarify how these NCCN criteria apply to breast cancer 
patients in the absence of a known familial mutation. Therefore, the criterion recommending 
testing based on a known deleterious BRCA1 or BRCA2 mutation as well as the criteria 
recommending testing based on family history in the case of an unaffected proband were 
excluded. 
A retrospective chart review of one-thousand-and-twenty-three M.D. Anderson Cancer 
Center patients with breast cancer was performed in order to evaluate the positive predictive 
values (PPVs) of fourteen individual criteria for predicting a BRCA1/2 mutation. Chart review 
involved the electronic medical record as well as a review of pedigrees through the Progeny 
database. All 1123 patients had a personal history of breast cancer or DCIS and all have had 
BRCA1/2 genetic testing with results available for review. These 1123 patients included male 
breast cancer patients who were seen for genetic counseling at MD Anderson between September 
9, 1999 and June 30, 2014 for a larger sample size due to the rareness of male breast cancers. 
Female patients included those seen for genetic counseling at our institution during a 15-month 
span from March 31, 2013 to June 30, 2014. Data gathered included the patient’s age at genetic 
testing, age at first breast cancer diagnosis, presence or absence of known Ashkenazi Jewish 
ancestry, hormone receptor status, additional cancer sites and ages at diagnosis, whether they 
fulfill each of the 14 criteria being evaluated, and genetic testing results.   
Of these 1123 patients, 26 had variants of unknown significance (VUS). These patients 
were excluded as it is uncertain whether they carry pathogenic mutations or benign variants, and 
therefore positive predictive values could not be calculated. An additional 25 patients were 
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excluded from this study as they underwent BRCA1/2 testing without having met any NCCN 
criterion for HBOC genetic testing. All 25 patients tested negative. While genetic testing is a 
personal decision that any individual can pursue, we did not include them in our analysis as our 
study focused on patients who are recommended for testing based on NCCN criteria.  
For the purposes of statistical analysis, the 1072 results were grouped into BRCA 1/2 
positive and BRCA1/2 negative. Positive results included those which were reported as 
‘deleterious’, ‘suspected deleterious’, and ‘see below’. A ‘see below’ result means that a 
deleterious mutation had been detected. However, the reporting laboratory commented that the 
cancer risks associated with the specific mutation may be lower than the generally quoted risk 
numbers for HBOC. We categorized these results as positive since they are foremost recognized 
damaging mutations, and still portend increased lifetime risks for breast cancer. Negative results 
included those which were reported as ‘likely benign’ and ‘no mutation detected’.  
Statistical analyses were performed on these 1072 in order to define patient 
demographics, categorize additional primaries, and calculate positive predictive values for 
patients meeting each criterion. Specifically, we wanted to challenge each criterion individually 
by calculating the PPV of each criterion when it is the only basis for which the patient was 
recommended to have genetic testing. This study also seeks to evaluate the PPV of when patients 
fulfill more than one criterion. 
 Patient demographics and characteristics were calculated and compared between BRCA 
positive and BRCA negative patients with chi-squared test. Wilcoxon rank-sum test was used to 
compare the age of cancer diagnoses between BRCA positive and BRCA negative patients. 
Positive predictive values were calculated for the 14 NCCN criteria being evaluated as well as for 
meeting only one criterion versus meeting more than one criteria using chi-squared test. Chi- 
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squared tests were also used to calculate whether any single or combined groups of 
criterion had PPVs significantly below 10%. 
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 RESULTS 
 
 Our study population of 1072 breast cancer patients pursued genetic testing between the 
years 1998 and 2014. While some individuals chose to pursue genetic testing during their MD 
Table 1. Study population demographics: comparison between BRCA1/2 positive and BRCA1/2 
negative groups 
 
Variable All Available BRCA1/2 
Positive 
BRCA1/2 
Negative 
P-value 
 
Gender 
    
Female  991 (92.4%) 90 (90.9%) 901 (92.6%) 0.5442 
Male  81 (7.6%) 9 (9.1%) 72 (7.3%)  
 
Mean age at genetic testing in years 
+/- SD (min, max) 
 
51.1 +/- 12.1, 
(23, 89) 
 
50 +/- 11.2, 
(26, 81) 
 
51.2 +/- 12.2, 
(23, 89) 
 
0.5322 
 
Mean age at first breast cancer 
diagnosis in years +/- SD (min, max) 
 
47.5 +/- 11 
(23, 87) 
 
44.9 +/- 8.7 
(28, 80) 
 
47.7 +/- 11.2 
(23, 87) 
 
0.0442 
     
Tumor staining for ER     
Positive  688 (64.2%) 38 (38.4 %) 650 (66.8%) <.0001 
Negative  281 (26.2%) 45 (45.5%) 236 (24.2%)  
Low Positive  28 (2.6%) 3 (3%) 25 (2.6%)  
Unavailable or equivocal 75 (7%) 13 (13.1%) 62 (6.4%)   
Tumor staining for PR     
Positive  583 (54.4%) 28 (28.3%) 555 (57%) <.0001 
Negative  367 (34.2%) 55 (55.6%) 312 (32.1%)  
Low Positive  34 (3.2%) 2 (2%) 32 (3.3%)  
Unavailable or equivocal   88 (8.2%) 14 (14.1%) 74 (7.6%)  
Tumor staining for HER2/neu     
Positive  130 (12.1%) 5 (5.1%) 125 (12.9%) 0.0284 
Negative  736 (68.7%) 72 (72.7%) 664 (68.2%)  
Unavailable or equivocal 206 (19.2%) 22 (22.2%) 184 (18.9%)  
 
Additional primaries 
    
Breast  113 (44.2%) 15 (51.7%) 98 (43.8%)  
Ovary* 24 (9.4%) 6 (20.7%) 15 (6.7%)  
Prostate  9 (3.5%) 0 (0%) 9 (4%)  
Pancreas  6 (2.3%) 2 (6.9%) 4 (1.8%)  
Other organ  
 
104 (40.6%) 6 (20.7%) 98 (43.7%)  
P-values from Wilconxon rank-sum test comparing BRCA1/2 positive and BRCA1/2 negative groups; 
*includes fallopian tube and primary peritoneal cancers  
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Anderson genetic counseling visit, other individuals have had previous genetic testing results 
from outside institutions, accounting for the wide range of years at BRCA1/2 genetic testing.  
 Tumors staining of ER, PR, and HER2/neu in breast tumors were obtained from the 
genetic counseling consultation notes. In the case of multiple breast primaries, the hormone 
receptor status of the breast cancer diagnosis that triggered the genetics evaluation was collected 
in this study. Hormone receptor tumor staining was categorized as the following: greater than 9% 
were considered positive, between 1 and 9% was considered low positive, and below 1% were 
considered negative. For the purposes of statistical analysis, low positive tumors were considered 
negative (Sanford, Song, Gutierrez-Barrera, Litton, Bedrosian, Albarracin, Valero, & Arun, 
2014). We evaluated the difference in PPV when using these “stricter” versus “looser” definition 
of triple negative diagnosed at or under age 60 in our analysis. When using the “looser” definition 
which includes those individuals with ER and/or PR receptors with low positive signals (staining 
between 1-9%),  3 out of 39 individuals tested positive for a PPV of 7.1% (1-19%, 95% CI). 
When using the “stricter” definition with ER and PR staining at below 1% signal, 3 out of 34 
individuals tested positive for a PPV of 8.1% (2-22%, 95% CI). 
 
Table 2. Composition of positive BRCA1/2 genetic testing results 
 
BRCA1 BRCA2 
54 deleterious 36 deleterious 
1 suspected deleterious 3 suspected deleterious 
1 see below 3 see below 
1 deleterious, also BRCA2 VUS  
 
 
 
 
The average age at time of BRCA1/2 genetic testing was 51.1 years, with a range of 23 
years to 89 years. The average age at first breast primary diagnosis was 47.5, with a range of 23 
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years to 87 years. The patients who tested BRCA1/2 positive averaged an age of 44.9 years 
compared to patients who tested negative at 47.7 years (p = 0.0442). This is a statistically 
significant age difference between these two groups. 
Estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 
(HER2/neu) hormone receptor statuses was collected and compared between those who tested 
positive and those who tested negative. Patients who were ER negative (p=<.0001) and/or PR 
negative (p=<.0001) and/or HER2/neu negative (p=0.0284) were more likely to be BRCA1/2 
positive. 
 Positive predictive values were calculated for all patients who met only one of 14 NCCN 
criteria versus those who met two or more NCCN criteria. Approximately 31.8% of breast cancer 
patients in our study population were recommended for testing on the basis of a single criterion. 
The PPV of 12% for meeting two or more criteria was significantly higher than the PPV of 3.2% 
for when a patient only met one criterion (p=<.0001).  This PPV is significantly below 10% 
(p=<.0001). 
 
 Positive predictive values were calculated for each of the 14 criteria when each was the 
sole criterion the patient met. One criterion had a PPV significantly below 10% by chi-square 
Table 3. Positive predictive values based on number of criteria fulfilled 
 
Number of 
criteria met 
BRCA1/2 
Negative 
BRCA1/2 
Positive 
Total PPV (95% CI) P-value 
1 329 11 341 3.2% (1.6% - 5.7%) <0.0001 
≥2 644 88 731 12.0% (9.8% -14.6%) 0.08 
Total 973 99 1072 
 
 
Chi-squared test comparing against 10% PPV 
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test. One hundred and fifteen patients were recommended for genetic testing based on fulfilling 
only the criterion of ‘diagnosed with breast cancer ≤45 years of age’. Of these 115 patients, only 
2 patients tested positive for a mutation in BRCA1 or BRCA2 for a PPV of 1.7%, which is 
significantly below the clinical utility cut-off of 10% for PPV (p = 0.001).  
Additionally, the positive predictive value of the criterion, “diagnosed with breast cancer 
at any age with ≥2 close blood relatives with breast cancer at any age” was calculated to be 0% 
(95% confidence interval of 0%-9.0%) as none of the 37 patients who were tested based solely on 
this criteria ended up testing positive for a mutation in BRCA1/2.  
Out of the 1072 BRCA1 and BRCA2 genetic testing results that were analyzed, 22 
(2.05%) patients had targeted analysis for three common Ashkenazi Jewish mutations, 7 (0.65%) 
patients had only sequencing analysis, 105 (9.79%) patients had only sequencing plus analysis for 
5 common rearrangements in BRCA, and 938 (87.5%) patients had comprehensive sequencing 
and rearrangement analysis. We do not expect this variation in the type of genetic testing to 
significantly impact our study outcomes as the 22 patients who underwent targeted analysis for 
three common Ashkenazi Jewish mutations did not go on to have sequencing or rearrangement 
analysis due to not having met additional criteria other than reported Ashkenazi Jewish ancestry. 
Certain patients who tested negative for a BRCA1/2 mutation carried mutations in other 
hereditary cancer syndrome genes. Three patients tested positive for mutations in TP53, and one 
had a VUS in TP53. One patient had a VUS in PTEN. One patient was positive for PTEN. One 
patient was positive for a MSH2 pathogenic mutation.   
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Table 4. Positive predictive values of individual NCCN criterion as sole basis for recommending testing  
NCCN Criterion 
BRCA1/2 
Negative 
BRCA1/2 
Positive 
PPV (95% 
Confidence 
Interval) 
P-value 
compared 
to 10% 
PPV 
 Diagnosed with breast cancer ≤45y 113 2 1.7% (0.2%, 6%) 0.001 
 Diagnosed with breast cancer ≤50y with a second 
breast primary at any age 
3 0 0% (0%, 71%) N/A 
 Diagnosed with breast cancer ≤50y with ≥1 close 
blood relative with breast cancer at any age 
19 0 0% (0%, 18%) N/A 
 Diagnosed with breast cancer ≤50y with unknown 
or limited family history 
17 0 0% (0%, 20%) N/A 
 Diagnosed with breast cancer ≤60y with triple 
negative hormone receptor status 
39 3 7.1% (1%, 19%) 0.7673 
 Diagnosed with breast cancer at any age with ≥1 
close blood relatives with breast cancer ≤50y 
20 0 0% (0%, 17%) N/A 
 Diagnosed with breast cancer at any age with ≥2 
close blood relatives with breast cancer at any age 
37 0 0% (0%, 9%) N/A 
 Diagnosed with breast cancer at any age with ≥1 
close blood relative with epithelial ovarian cancer 
27 2 6.9% (0.8%, 23%) 0.8699 
 Diagnosed with breast cancer at any age with ≥1 
close blood relative with ≥2 close blood relatives 
with pancreatic cancer and/or prostate cancer 
(Gleason score ≥7) at any age 
3 0 0% (0%, 71%) N/A 
 Diagnosed at any age with a close male relative 
with breast cancer 
4 0 0% (0%, 60%) N/A 
 Personal history of epithelial ovarian cancer 10 1 9.1% (0.2%, 41%) 1.0000 
 Personal history of male breast cancer 28 2 6.7% (0.8%, 22%) 0.8227 
 Diagnosed at any age as an individual of ethnicity 
associated with higher mutation frequency (e.g., 
Ashkenazi Jewish) 
9 1 10% (0.3%, 45%) 0.8025 
 Personal history of pancreatic cancer or prostate 
cancer (Gleason score ≥7) at any age with ≥2 
close blood relatives with breast and/or ovarian 
and/or pancreatic or prostate cancer (Gleason 
score ≥7) at any age 
No patients fulfilled only this criterion 
Two-sided exact test comparing against 10% PPV 
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DISCUSSION 
 
Conclusions 
Out of 14 NCCN criteria evaluated from the “Genetic/Familial High-Risk Assessment: 
Breast and Ovarian Version 2.2014” guidelines for recommending genetic testing, 12 criteria did 
not have PPVs statistically significantly differing from 10% PPV, and 2 did had positive 
predictive values significantly below 10% for predicting a mutation in BRCA1 and BRCA2.This 
data suggests that possible revisions may be necessary in future versions of these specific NCCN 
guidelines in order to improve clinical utility of when to recommend genetic testing for HBOC.  
The current NCCN guidelines recommend BRCA1/2 testing for any patient that meets 
one or more criterion. From our study, individuals who fulfilled only one criterion had a 3.2% 
(0.2-6%) chance to test positive for a BRCA1/2 mutation. This PPV is significantly below that of 
the clinical utility cut-off of 10%. Interestingly, previous studies suggest that the incidence of 
BRCA1/2 mutations in women with breast cancer up to age 70 is between 1% and 6% (Frank & 
Critchfield, 2001; McClain, Palomaki, Nathanson, & Haddow, 2005). This suggests that the 
population of individuals who meet only one NCCN criterion for testing may not be a population 
enriched in BRCA1/2 mutations. 
Patients who meet more than one criterion for testing are more likely to test positive for a 
BRCA1/2 mutation, and may need to be counseled differently from those who fulfill only one 
criterion. In our study, individuals who met two or more criterion had a 12% (9.8-14.6%, 95% 
CI) likelihood of having a mutation in BRCA1 or BRCA2.  Meeting more than one criterion 
correlated with having a higher risk for HBOC.  
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A previous study estimates the mutation rate in women diagnosed with breast cancer by 
age 45 to be between 4% and 8% (McClain, Palomaki, Nathanson, & Haddow, 2005).In our 
study, there 115 patients who were recommended for testing solely based on having fulfilled the 
criterion of being diagnosed with breast cancer by age 45. There were 441 additional patients who 
were recommended for testing based on having fulfilled this criterion as well as one or more other 
criterion. In total, 56 out of the 556 patients who fulfilled this criterion tested positive for a 
BRCA1/2 mutation for a yield of 10.1% overall. Of the 115 patients who were tested solely based 
on being diagnosed with breast cancer by age 45, the positive predictive value for a BRCA1/2 
mutation was 1.7% (0.2-6%, 95% CI). This suggests that testing individuals based on this 
criterion alone may in fact be testing individuals at or below the incidence of HBOC in the 
general breast cancer population, and that individuals with a BRCA1/2 mutation will often fulfill 
at least one other criterion, which helps identify a population at higher risk within the young 
(≤45years) breast cancer population.  It would be worth investigating the clinical usefulness of 
this criterion in consideration of the costs and harms associated with genetic testing with low 
yield.  
 In 2014 Dr. Mary Claire King made a public declaration recommending testing of all 
women at age 30, regardless of personal and family histories, for BRCA1/2 genetic testing based 
on an estimated population prevalence higher than the 1in 400 to 1 in 800 that is generally quoted 
(King, 2014). While our study was not aimed to assess the effectiveness of this approach, it may 
still be useful to consider BRCA1/2 testing at a population level. Based on our findings, it may be 
noted that portions of the currently accepted practice guidelines recommend genetic testing at a 
yield comparable to the prevalence of BRCA1/2 mutations in the general population. Thus, it may 
be effective to discuss the option of BRCA1/2 testing with all patients with breast cancer.  
These considerations are especially important in the atmosphere of genetic testing for 
cancer predisposition syndromes in recent years. Genetic testing has become increasingly 
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accessible to patients due to the decrease in cost of sequencing technologies. Further, large panels 
of cancer predisposition genes are being marketed to non-specialized oncologists in many large 
cities. As there are fewer and fewer barriers to offering genetic testing, it is more important now 
than critically evaluate the purpose of existing guidelines when looking forward to the future of 
genetic testing.  In the case of the BRCA genes, the time may soon come when reduced cost, 
decreased stigma, and variant reclassification sophistication may finally allow for successful 
population-based testing. However, the challenge of providing appropriate counseling to all 
interested patients regarding risks and limitations of existing knowledge still remains.  
 
Limitations 
Due to limitations in sample size, several of the criteria being evaluated did not meet 
clinical significance. Because many criteria overlap, there were several criteria for which it was 
rare to be the sole criterion for which patients were recommended for testing. Therefore, the 
number of individuals who were tested solely based on having met one criterion was only a 
fraction of all patients in the study. However, the current data supports the idea that these criteria 
vary in their predictive values. As there is clear value in understanding these predictive values, a 
large-scale analysis of the detection rates, specificity, and positive predictive values of guidelines 
for HBOC genetic testing may be beneficial to provide specific clinical guidance and 
expectations. 
Furthermore, our study population was likely biased towards being a higher-risk sample 
as they are patients who have been referred to genetic counseling out of concern for a hereditary 
cancer syndrome. This does potentially skew the results of our study. However, due to our aim to 
identify criteria with mutation yields, our presumably higher-risk population in fact strengthens 
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our findings. In other words, if a criterion has a low yield in a high-risk population, it likely has 
an even lower yield in the general breast cancer population. 
Our study population consisted of only participants with a personal history of breast 
cancer. Evaluation of the criteria, “personal history of pancreatic cancer or prostate cancer 
(Gleason score ≥7) at any age with ≥2 close blood relatives with breast and/or ovarian and/or 
pancreatic or prostate cancer (Gleason score ≥7) at any age” and “personal history of epithelial 
ovarian cancer”, were limited due to the nature of these criteria not requiring the patient to have a 
personal history of breast cancer. 
While it was possible to verify details of the patients’ personal histories of cancer, family 
histories were collected by patient report. As is often the case in patient-reported family history, 
there can be reports of ambiguous or unknown types of cancer, such reports of “female cancers” 
or “unknown primaries”. Furthermore, we were not able to verify the exact pathology of family 
members’ reports of cancer such as epithelial versus mucinous ovarian cancer and the Gleason 
score of prostate cancers. However, as the NCCN guidelines are intended as clinical criteria, we 
feel that this information is often difficult to obtain in a clinical setting. Therefore, our study 
realistically represents typical information that would be available in a high-risk cancer genetics 
consultation. 
While the majority of our patients did undergo BRCA1 and BRCA2 sequencing and 
rearrangement analysis, there were 112 patients who did not have comprehensive testing. It is 
likely that very few would have tested positive on follow-up rearrangement testing. Large 
rearrangements account for approximately 5.9%-9.9% (Judkins, Rosenthal, Arnell, Burbidge, 
Geary, Barrus, Schoenberger, Trost, Wenstrup, & Roa, 2012) of pathogenic mutations in HBOC, 
mostly in BRCA1. These are patients who are likely to have more concerning family histories due 
to the higher penetrance of cancers in BRCA1-associated HBOC. Furthermore, 105 of 112 
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patients without full rearrangement analysis still had 5-site rearrangement analysis, which 
accounts for the most common pathogenic rearrangements affecting BRCA1.   
 
Future Directions 
Triple negative breast cancers are historically defined as those with tumor staining of less 
than 1% for ER, PR, and HER2/neu. In this study, a looser definition was used when evaluating 
the criterion of being “diagnosed with breast cancer ≤60y with triple negative hormone receptor 
status”.  For the purposes of this study, we defined triple negative tumor staining levels less than 
9%. This was due to recent data demonstrating similar BRCA1/2 mutation prevalence rates in 
hormone receptor negative and low positive groups (Sanford, Song, Gutierrez-Barrera, Litton, 
Bedrosian, Albarracin, Valero, & Arun, 2014). However, more studies are needed to confirm this 
association. The sample number in our study was not large enough to detect a significant 
difference. However, this topic warrants additional investigation in order to further define “triple 
negative” in the context of association with HBOC syndrome. 
Currently there exist risk-assessment models for prediction of future risks for breast 
cancer, as well as risk-prediction tools that use family history to predict the likelihood of 
detecting a BRCA1/2 mutation, such as BRCAPRO. However, these risk prediction tools can be 
time-consuming and are typically not used during the face-to-face time with the patient in order 
to make a decision on testing. Being able to generate an empiric likelihood for testing positive 
based on which NCCN criteria they fulfill, however, could offer more concrete information to the 
patient during the session in order to aid decision-making regarding testing and for anticipatory 
guidance. In this consideration, it is important to balance the goals and costs associated with each 
risk-assessment tool. Goals may include the accuracy of the tool and ease of usage in clinic. Costs 
may include the time, expertise, or specialized equipment that may be required to run the tool. 
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While this is outside of the scope of the current study, it may be of interest to assess the predictive 
value of these tools in comparison with the NCCN criteria to predict BRCA1 and BRCA2 
positivity. No clinical guideline is perfect. It is always important to evaluate each family with a 
fresh eye. With that said, the ultimate goal would be to have a system, whether by a set of 
guidelines or by an automated pedigree- and pathology- assessment tool, that would allow for the 
most accurate risk estimate for our patients without undue burden on the healthcare infrastructure.  
There may be clinical value in conducting similar evaluations of current NCCN criteria 
for recommending testing for other hereditary cancer syndromes such as Li-Fraumeni syndrome, 
Cowden syndrome, Lynch syndrome, familial adenomatous polyposis, MUYTH-associated 
polyposis, and Peutz-Jeghers syndrome. 
Lastly, the data from this study provides practical implications. The empiric risk numbers 
from this study can be utilized to provide patients with an approximate chance for testing positive 
according to the specific NCCN criteria they fulfill. For patients who only fulfill a single 
criterion, it would be appropriate to inform them of the relative low likelihood of testing positive. 
For those who fulfill multiple criteria, we are able to have a discussion with more time dedicated 
to the next steps in the case of a positive test. While this also was not a goal of our study, and not 
a large sample, we do feel reassured that, in this 15-month period, every breast cancer patient 
who pursued BRCA1/2 testing despite not having been recommended to do so based on the 
NCCN guidelines all tested negative and are likely truly at low risk.  
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SUPPLEMENTAL DATA 
The subset of current NCCN criteria being evaluated includes (from ‘Genetic/familial high-risk 
assessment: breast and ovarian. Version 1.2014’, © National Comprehensive Cancer Network, 
Inc 2011, All Rights Reserved.  NATIONAL COMPREHENSIVE CANCER NETWORK®, 
NCCN®, NCCN Guidelines
®
, NCCN COMPENDIUM
®
 and NCCN TEMPLATES
®
 are 
trademarks owned by the National Comprehensive Cancer Network, Inc.) 
Hereditary Breast and/or Ovarian Cancer syndrome testing criteria
 
 
 Personal history of breast cancer + ≤1 of the following : 
o Diagnosed ≤45y 
o Diagnosed ≤50y with: 
 An additional primary 
 ≥1 close blood relative with breast cancer at any age 
 An unknown or limited family history  
o Diagnosed ≤60y with a: 
 Triple negative breast cancer (hormone receptors: ER -, PR-, HER2/neu-
) 
o Diagnosed at any age with: 
 ≥2 close blood relatives with breast cancer at any age 
 ≥1 close blood relative with epithelial ovarian cancer 
 ≥2 close blood relatives with pancreatic cancer and/or prostate cancer 
(Gleason score ≥7) at any age 
 A close male blood relative with breast cancer 
 For an individual of ethnicity associated with higher mutation frequency 
(e.g., Ashkenazi Jewish) no additional family history may be required 
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 Personal history of epithelial ovarian cancer 
 Personal history of male breast cancer 
 Personal history of pancreatic cancer or prostate cancer (Gleason score ≥7) at any age 
with ≥2 close blood relatives with breast and/or ovarian and/or pancreatic or prostate 
cancer (Gleason score ≥7) at any age 
o For pancreatic cancer, if Ashkenazi Jewish ancestry, only one additional affected 
relative is needed) 
Individuals with unknown or limited family history/structure, such as fewer than 2 first- or 
second-degree female relatives having lived beyond age 45 in either lineage, may have an 
underestimated probability of familial mutation detection. The likelihood of mutation detection 
may be very low in families with a large number of unaffected female relatives. Clinical judgment 
should be used to determine the appropriateness of genetic testing. The maternal and paternal 
sides should be considered independently. 
For the purposes of these guidelines, invasive and ductal carcinoma in situ breast cancers should 
be included 
Two breast primaries includes bilateral (contralateral) disease or two or more clearly separate 
ipsilateral primary tumors either synchronously or asynchronously 
Close blood relatives include first-, second-, and third-degree relatives on same side of family. 
For the purposes of these guidelines, fallopian tube and primary peritoneal cancers are included.  
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